Helicobacter pylori: Why are eradication results so variable?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 6, 2004, Pages 606-609

  Katelaris, Peter H ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; CITRIC ACID; CLARITHROMYCIN; METRONIDAZOLE; NITROIMIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CLINICAL TRIAL; DIARRHEA; DISEASE CONTROL; DYSPEPSIA; EDITORIAL; GEOGRAPHY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCIENTIFIC LITERATURE; SIDE EFFECT; SMOKING; TASTE DISORDER; TREATMENT FAILURE;

EID: 3042780430     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03453.x     Document Type: Editorial

References (38)

1. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment. Pharmacol. Ther. 1999; 13: 857-64.
2. European Helicobacter pylori study Group. Current European concepts on the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13.
3. Katelaris PH, Forbes G, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 2002; 123: 1763-9.
4. Gisbert JP, Gonzalez L, Calvet X et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment. Pharmacol. Ther. 2000; 14: 1319-28.
5. Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment. Pharmacol. Ther. 2003; 17: 1137-43.
6. Laine L, Fennerty MB, Osato M et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am. J. Gastroenterol. 2000; 95: 3393-8.
7. Lind T, Veldhuyzen van Zanten S, Unge P et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH 1 study. Helicobacter 1996; 1: 138-44.
8. Lind T, Megraud F, Unge P et al. The MACH 2 Study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-53.
9. Bhatia V, Ahuja V, Das B, Bal CS, Sharma MP. Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity. J. Gastroenterol. Hepatol. 2004; 19: 619-25.
10. Graham DY, Lew GM, Malaty HM et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1993; 102: 493-6.
11. Qasim A, O'Morain CA. Treatment of Helicobacter pylori infection and factors influencing eradication [Review]. Aliment. Pharmacol. Ther. 2002; 16 (Suppl. 1): 24-30.
12. Houben MH, Van Der Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment. Pharmacol. Ther. 1999; 13: 1047-55.
13. van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am. J. Gastroenterol. 1999; 94: 1751-9.
14. Penston JG. Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment. Pharmacol. Ther. 1994; 8: 369-89.
15. Katelaris PH, Adamthwaite D, Midolo P, Yeomans N, Davidson G, Lambert J. Randomised trial of omeprazole and metronidazole with either amoxycillin or clarithromycin for the eradication of H. pylori in a region of high metronidazole resistance - the HERO study. Aliment. Pharmacol. Ther. 2000; 14: 751-8.
16. Bardhan K, Bayerdorffer E, Veldhuyzen Van Zanten SJ et al. The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter 2000; 5: 196-201.
17. de Boer WA, Driessen WM, Potters VP, Tytgat GN. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am. J. Gastroenterol. 1994; 89: 1993-7.
18. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment. Pharmacol. Ther. 2002; 16: 167-80.
19. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am. J. Gastroenterol. 2003; 98: 562-7.
20. Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM. Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week - a meta-analysis of efficacy. Aliment. Pharmacol. Ther. 2000; 14: 1141-50.
21. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 2001; 20: 820-3.
22. Goh K, Parasakthi N, Cheah P et al. Efficacy of a 1-week pantoprazole triple therapy in eradicating Helicobacter pylori in Asian patients. J. Gastroenterol. Hepatol. 2000; 15: 910-14.
23. Fock KM, Chelvam P, Lim SG. Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. Aliment. Pharmacol. Ther. 2000; 14: 225-31.
24. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J. Gastroenterol. Hepatol. 1998; 13: 1-12.
25. Mukhopadhyay AK, Kersulyte D, Jeong JY et al. Distinctiveness of genotypes of Helicobacter pylori in Calcutta, India. J. Bacteriol. 2000; 182: 3219-27.
26. Chowdhury A, Berg DE, Jeong JY, Mukhopadhyay AK, Nair GB. Metronidazole resistance in Helicobacter pylori: magnitude, mechanism and implications for India. Indian J. Gastroenterol. 2002; 21: 23-8.
27. Wermeille J, Cunningham M, Dederding JP et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterol. Clin. Biol. 2002; 26: 216-19.
28. Datta S, Chowdhury A, Mukhopadhyay AK, Bhattacharya SK, Berg DE, Nair GB. Molecular and evolutionary genetics and drug resistance of the gastric pathogen, Helicobacter pylori. Indian J. Med. Res. 2002; 115: 73-101.
29. Chaudhuri S, Chowdhury A, Datta S et al. Anti-Helicobacter pylori therapy in India: differences in eradication efficiency associated with particular alleles of vacuolating cytotoxin (vacA) gene. J. Gastroenterol. Hepatol. 2003; 18: 190-5.
30. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23: 460-71.
31. Inaba T, Mizuno M, Kawai K et al. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J. Gastroenterol. Hepatol. 2002; 17: 748-53.
32. Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy - results of an individual data analysis of 2751 patients. Aliment. Pharmacol. Ther. 2003; 17: 99-109.
33. Spiller RC. Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia? Eur. J. Gastroenterol. Hepatol. 1999; 11 (Suppl. 2): S25-8; discussion S43-5.
34. Working Party of the European Helicobacter Study Group. Guidelines for Clinical trials in H. pylori infection. Gut 1997; 41 (Suppl. 2): S10-18.
35. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 14: 1191-4.
36. Bhasin DK, Sharma BC, Ray P, Pathak CM, Singh K. Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori: a report from India. Helicobacter 2000; 5: 84-7.
37. Pai CG, Thomas CP, Biswas A, Rao S, Ramnarayan K. Quadruple therapy for initial eradication of Helicobacter pylori in peptic ulcer: comparison with triple therapy. Indian J. Gastroenterol. 2003; 22: 85-7.
38. Proceedings of the 2nd National Workshop on Helicobacter pylori. Management recommendations in India. Thrissur, Kerala, February 20, 1999. Indian J. Gastroenterol. 2000; 19 (Suppl. 1): S1-40.